Development of HTLV-I-specific anti-cancer therapy by using single chain T cell receptors and single chain trimers of MHC-I.
| Project/Area Number |
24590547
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Virology
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
OHASHI Takashi 北海道大学, 遺伝子病制御研究所, 准教授 (10282774)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | HTLV-I / 成人T細胞白血病 / 動物モデル / 免疫治療 / ウイルス療法 / ATL / Tax / CTL / T細胞受容体 / single chain trimer / MHC-I / Single chain trimer |
|---|
| Outline of Final Research Achievements |
The potential for novel therapies against Human T-cell leukemia virus type I (HTLV-I) induced-adult T-cell leukemia (ATL) has been assessed in an originally developed rat model of HTLV-I infection. The results indicate that combined treatment with m8Δ/RT1AlSCTax180L, which can express a single chain trimer of rat MHC-I with a Tax-epitope, and the epitope-specific CTL line, 4O1/C8, increased the cytolysis of FPM1V.EFGFP/8R cells, a CTL-resistant subclone of HTLV-I-infected FPM1 cells, compared with that using 4O1/C8 and m8Δ presenting an unrelated peptide, suggesting that the activation of 4O1/C8 by m8Δ/RT1AlSCTax180L further enhanced the killing of the HTLV-I-infected cells. Our results indicate that combined therapy of oncolytic m8Δ/RT1AlSCTax180L, and HTLV-I-specific CTLs may be effective for eradication of HTLV-I-infected cells, which evade from CTL lysis and potentially develop ATL. The present results should be useful for further verifying the strategies to fight against ATL.
|
Report
(4 results)
Research Products
(6 results)
